A Functional Analysis of Arginine Methylation
- Institution
- UNIVERSITY OF TX MD ANDERSON CAN CTR, TX
- Principal investigator
- Mark T. Bedford
- Funding
- $405K
- Duration
- 2024–2029
Moonbase score
Still being scored
Abstract
PROJECT SUMMARY/ABSTRACT Our goal is to broadly understand the biological roles of arginine methylation, a very common post-translational modification (PTM). This PTM is deposited by at least nine protein arginine methyltransferases (PRMTs) in mammals. Like lysine methylation, arginine methylation of a substrate often recruits an effector molecule to the newly created methyl-motifs. Unlike lysine methylation, relatively few effects have been identified for methylarginine marks. This paucity of identified methylarginine (Rme) mark effectors and the signaling roles of the known effectors define a knowledge gap that will be addressed here. By performing proteomic screens, we have identified a novel reader for Rme marks, called SART3. This effector does not harbor a Tudor domain which is usually found in “traditional” readers of Rme marks, but rather it carries a series of HAT (Half-a-TPR) repeats that are rich in aromatic amino acids. Here, we plan to characterize this interaction and investigate the possibility that other TPR repeat-containing proteins may be involved in sensing arginine methylation. Also, we are investigating the functions of two known effects of Rme marks, called SND1 and TDRD3. Through a combination of mouse work and protein array studies, we have determined that SND1 can likely directly activate the kinase activity of S6K2, and that TDRD3 can play a role in the DNA damage response.
LOADING MOONBASE SCORE
Questions for UNIVERSITY OF TX MD ANDERSON CAN CTR
Answered by the team behind this research.
No questions yet. Sign in to ask the first one
Related grants
Same institution, same topic, scored first.
- NIH · University of TX MD Anderson Can Ctr49
Targeting STAT3 for the Treatment of CDK4/6 Inhibitor Resistant Advanced Estrogen Receptor Positive Breast Cancer Patients
Khandan Keyomarsi · $428K · 2020–2026
- NIH · University of TX MD Anderson Can Ctr47
Ph1/2 Study of the Imipridone ONC201 for Treatment of AML IND125,203 (12/23/2014)
Michael Andreeff · $461K · 2019–2027
- NIH · University of TX MD Anderson Can Ctr46
Modulation of intracellular lipid access by ATGL determines ferroptosis sensitivity in castration-resistant prostate cancer
Pham Hong Anh Cao · $39K · 2025–2027